MDNA11

Medicenna Therapeutics, Inc. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	MDNA11
Also known as	Interleukin-2 (IL-2)-albumin
Sponsor	Medicenna Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Beta-only IL-2 ImmunoTherapY Study (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MDNA11 CI brief — competitive landscape report
MDNA11 updates RSS · CI watch RSS
Medicenna Therapeutics, Inc. portfolio CI